Latest / Investor Exchange / How Vietnam Is Negatively Impacting Hyphens Pharma's Growth

Transcript

How Vietnam Is Negatively Impacting Hyphens Pharma's Growth · Investor Exchange

0:02
Time for another Investor Exchange podcast. Here are your hosts, Matt and Sally.
0:07
Imagine seeing a company's sales drop by like nearly 10% in a single year.
0:13
Right, which usually spells disaster. Exactly.
0:16
But somehow they end up generating 44% more cash than Wall Street analysts expected.
0:22
It's the ultimate investor magic trick. It really is a massive contradiction.
0:26
Yeah, you're looking at a shrinking top line, but a wildly expanding cash position.
0:30
And today, we are figuring out exactly how that trick is performed.
0:35
Welcome to the Deep Dive. Glad to be here. So we are putting on our investor
0:39
hats today to pick apart a fresh equity research report.
0:42
This is from Evolve Capital, dated April 9th, 2026.
0:46
And the subject is the 2025 financial year earnings update for Hyphens Pharma.
0:52
And, you know, for anyone who tracks the Southeast Asian health care sector.
0:56
Hyphens Pharma is a really fascinating case study right now.
0:59
Yeah, they operate as a specialty pharmaceutical and consumer health care group, right?
1:03
Across places like Indonesia, Malaysia, the Philippines and Vietnam.
1:07
That's right. And the Evolved Capital Report, well, it slaps a neutral rating
1:10
on the stock with a target price of 32 Singapore cents.
1:14
Which ironically happens to be exactly where the stock is trading today.
1:17
Spot on. I mean, usually when I read a report where the target price matches
1:23
the current price to the penny, the analyst is basically saying the stock is
1:27
perfectly priced and nothing interesting is happening. It's like a car idling at a red light.
1:32
Right. The interest is running smoothly, but we're just waiting.
1:35
Exactly. Waiting to see what will actually press the gas pedal to drive the
1:39
stock forward. It definitely looks like a wait and see situation on the surface. Yeah.
1:44
For investors, a neutral rating is not a signal to just ignore the stock. No. No, not at all.
1:51
When a company is sitting right at fair value while reporting these kinds of
1:55
contradictory numbers, it means we have to look under the hood.
1:58
Okay, so what are we looking for?
2:00
Well, we need to look at the quality of their earnings, the cash they're throwing
2:03
off, and the way they're navigating some major structural challenges in emerging markets.
2:08
That is where the actual story is. I'm glad you brought that up because the
2:12
headline numbers in this report, they really pull you in opposite directions. They absolutely do.
2:16
Like total revenue fell by 9.2% from the previous year, landing at $177.4 million Singapore dollars.
2:24
And usually almost a 10% drop in sales triggers a massive sell-off.
2:30
Right. It would if you only looked at the top line. But here's the plot twist.
2:34
The gross profit, which came in at $72.2 million Singapore dollars, it didn't drop at all.
2:40
Wait, really? It just stayed flat? It remained completely steady.
2:43
And because of that, their gross profit margin actually expanded significantly.
2:48
It went up to 40.7%. Okay, I have to pause here because the math feels entirely
2:53
counterintuitive for a business that distributes physical products.
2:56
It sounds like it, yeah. I mean, if you are moving fewer boxes out of the warehouse,
3:00
how in the world are their core operating earnings beating analyst estimates by over 12 percent?
3:06
You can't just magically make more money by selling less stuff.
3:09
Well, you can if you drastically change the mix of the stuff you're selling. Oh, I see.
3:14
Evolve Capital points out that this isn't a magic trick. It's a deliberate pivot.
3:18
They're basically walking away from or losing high volume but low margin sales.
3:22
And replacing them with what? With lower volume, but incredibly high in sales.
3:28
So the actual quality of every dollar coming in the door is much,
3:32
much higher than it was a year ago.
3:33
OK, so the revenue they are keeping is much more profitable.
3:36
I get that. But then the report hits us with another massive contradiction. The net profit miss.
3:42
Yes. If operating margins are expanding so beautifully, why did their bottom
3:47
line net profit miss estimates?
3:49
They only posted 5.8 million Singapore dollars. I know, the net profit mist
3:54
looks bad, until you read the footnotes.
3:56
The report attributes that miss to 7.6 million Singapore dollars in non-recurring
4:01
losses. So just one-off expenses.
4:04
Exactly. Restructuring costs, accounting adjustments, things that do not reflect
4:08
the day-to-day health of selling pharmaceuticals. Okay.
4:10
If you strip away those one-time charges, the underlying business is actually humming.
4:15
And I guess the proof of that humming engine is the cash flow from operations.
4:19
Because this is the number that completely shocked me. Oh, it's huge.
4:22
18.7 million Singapore dollars in operational cash flow. That is a 44% beat
4:28
against what analysts were expecting. It is a phenomenal number.
4:32
I mean, you can manipulate net profit with accounting maneuvers,
4:35
but you cannot fake cash in the bank. Right. Cash is cash.
4:40
Exactly. That 18.7 million Singapore dollars is hard currency generated from
4:45
their daily operations.
4:47
Which translates directly to the listener's wallet, really.
4:51
Because they are generating such heavy cash flow, Hyphens Pharma maintained
4:55
a very healthy dividend.
4:57
Yeah, 1.50 Singapore cents per share. Right.
5:00
So if you buy the stock at its current price, you are locking in a solid 4.7% dividend yield.
5:07
Plus they're sitting on a net cash balance sheet. Meaning they have more cash on hand than debt.
5:12
Exactly. Which is what you want to see. It's exactly what you want when a company
5:16
is going through a transitional phase.
5:18
They're essentially paying you a nearly 5% yield simply to hold the stock while
5:23
management figures out the next phase of growth.
5:25
It's basically paid waiting time. But to understand why the revenue dropped
5:29
but the margins improved, we have to start looking at the whole pie and break
5:32
the company down to its three main divisions.
5:35
Right, because the drop wasn't spread out evenly. No, it was highly concentrated.
5:39
Let's talk about the anchor dragging down the top line. Pharmaceuticals and
5:43
medical aesthetics, it's their largest division.
5:45
And revenue there plunged by 18.4%, dropping down to 101.3 million Singapore dollars.
5:54
And the geographic culprit is really clear in the report.
5:57
It's Vietnam, revenue there collapsed by nearly 31%. Yeah, the structural economics
6:02
of operating in Vietnam right now are just punishing.
6:06
And it really comes down to foreign exchange mechanics. Okay,
6:09
let me try to map out the mechanics of this squeeze using an everyday analogy
6:12
just to make sure I am visualizing this correctly.
6:15
Imagine it's like running a bakery where you have to buy your flour in expensive euros, right?
6:21
Okay, tracking so far. But the government forces you to sell your bread in a
6:25
local currency that, well, keeps losing its value.
6:28
So your costs are high and rigid, but the actual purchasing power of your revenue
6:32
is just evaporating. That is the exact trap Hyphens Pharma has caught in.
6:37
They source products from European suppliers who expect to be paid in strong euros.
6:41
But Hyphens sells these medical products under the heavy regulatory framework
6:46
of the Vietnamese government. And the government controls the health care pricing.
6:49
Exactly. So they can't simply hike prices to cover the currency difference.
6:54
As a report highlights, the Vietnamese currency is on track for its fourth consecutive
6:59
year of depreciation against the dollar.
7:02
So they're trapped between European inflation on the supply side and strict
7:06
price controls on the demand side. With a depreciating currency in the middle.
7:10
But the report also mentions an accounting shift that made the Vietnam numbers
7:15
look even worse than they organically were. Oh, right.
7:18
Management decided to revise their consignment methodology there, right? Yes.
7:23
During the second half of the 2025 financial year, they changed the way they recognized sales.
7:27
They shifted from a six-month average down to a three-month average.
7:31
I was wondering about that. Why do that in the middle of a terrible year?
7:34
It feels like kicking yourself when you are already down.
7:36
It actually is a very prudent move, even if it hurts.
7:40
When a market is deteriorating, a six-month average creates a lag.
7:44
Oh, because it blends in older, better data. Exactly. It paints an artificially rosy picture.
7:51
Moving to a three-month average gives management and investors a much more accurate,
7:56
real-time read on their inventory and sales.
7:59
Okay, but there's an immediate penalty for making that change,
8:01
right? Yeah. It wiped out $1.6 million Singapore dollars in recognized revenue for the year.
8:06
They essentially ripped the Band-Aid off to reset the baseline.
8:10
Well, they take the hit now to ensure the books are clean moving forward.
8:13
Makes sense. But if pharmaceuticals and medical aesthetics is the anchor,
8:18
we eagerly need to pivot to the star of this earnings report.
8:21
The proprietary brands division. Yes. This is where they actually own the brands.
8:26
And revenue here surged over 33 percent, hitting 36.7 million Singapore dollars.
8:32
It's a great number. Though Evolve Capital does note that part of that massive
8:35
jump is due to some internal brand reshuffling.
8:38
Right. They reclassified some existing products into this specific division. True.
8:43
So the 33 percent figure is slightly padded.
8:46
However, beyond that reshuffling, the analyst points out that management still
8:50
reported real organic growth in their core established brands.
8:55
Like Saratin and Ocean Health. Exactly. That is real fundamental growth.
8:59
And as an investor, this is where the future growth narrative actually lives.
9:03
It's not just about established products. It's about the new pipeline,
9:06
like that acne treatment, Winleby.
9:08
Oh, yeah. They recently launched it in Singapore and Malaysia.
9:11
And it seems to be gaining serious traction with dermatologists,
9:15
according to the report.
9:16
Which is huge because getting buy-in from medical professionals is incredibly difficult.
9:20
Yeah. But once a dermatologist starts prescribing your proprietary product...
9:24
That revenue becomes sticky. Incredibly sticky.
9:27
It becomes a high-margin recurring revenue stream. But the detail in the proprietary
9:31
brand section that really blew me away was their geographic expansion.
9:34
They just out-licensed one of their products to a European company for a 2026
9:40
rollout. Yes, Serapro MED.
9:42
They licensed it to a company called Luis Widmer.
9:46
Completely changes their margin trajectory. Okay, walk us through the mechanics
9:50
of that out-licensing deal, because it sounds like a game changer. It really is.
9:55
Think back to the Vietnam problem we discussed earlier.
9:58
In Vietnam, Hyphens is the distributor taking on all the currency risk and the regulatory headaches.
10:04
Right, while the European supplier just collects its money. Exactly.
10:08
But by out-licensing Serapro MED to Louis Widmer, Hyphens flips the script.
10:14
Now, Hyphens is the one holding the intellectual property. Oh, wow.
10:17
Yeah, they don't have to build European warehouses, hire sales teams,
10:20
or navigate European regulations.
10:23
Louis Widmer does all the heavy lifting, and Hyphens simply collects a royalty.
10:27
So it's almost pure profit dropping straight to the bottom line. It really is.
10:31
They completely reverse the polarity of their own business model.
10:34
That perfectly explains the margin expansion.
10:36
Now, what about their third division, the digital platform and e-pharmacy?
10:40
It's their smallest segment, Revenue dropped by about 10%, coming in at 39.4
10:45
million Singapore dollars.
10:47
A drop in revenue in the digital space usually signals a platform that's,
10:51
you know, losing its user base.
10:53
In this case, though, management has been actively pruning the portfolio.
10:58
They are deliberately cutting away
11:00
low-margin digital sales to focus on profitability. And is it working?
11:05
It appears to be, because despite the drop in overall digital revenue,
11:09
their operating losses in this division actually shrank year over year.
11:13
Okay, but Evolve Capital did throw a minor caution flag into the report regarding
11:18
the digital segment, specifically in Vietnam.
11:21
Right. They highlighted a small $600,000 Singapore dollar provision for bad
11:26
debt. Which was a loan to a Vietnam partner, right?
11:28
Yes, to help facilitate their digital expansion there.
11:31
And taking a provision means they are officially acknowledging they might never
11:34
see that money again. Wow. So even in the digital space, Vietnam is a struggle.
11:38
Yeah. While 600,000 Singapore dollars won't sink a company generating 18 million
11:43
in cash flow, it signals that their digital operations there are struggling to gain traction.
11:48
It always circles back to Vietnam. So we've looked backward at 2025.
11:52
Let's shift the timeline and look forward to the rest of 2026 and 2027.
11:56
What is the market pricing in for the future?
11:59
Well, this is exactly why the analyst remains neutral. The stock is currently
12:03
trading at roughly 11 times its expected 2026 earnings. Which is fairly conservative.
12:09
It is. The expectation is that earnings will slowly normalize.
12:13
But the report explicitly states there is no massive step change event on the
12:18
horizon to rocket the stock upward.
12:21
Meaning there's no clear catalyst. Right.
12:24
No enormous acquisition or a sudden regulatory change. It'll just be incremental growth.
12:29
I do want to question that 11 times valuation, though.
12:32
The report runs a comparison against regional peers, and they highlight Calbee
12:35
Pharma, which is trading at a much richer valuation.
12:38
Why does Hyphens Pharma trade at a discount compared to them?
12:41
It simply comes down to scale and margin size.
12:44
Colby Pharma is a dramatically larger enterprise. When institutional investors
12:47
manage billions of dollars, they need highly liquid stocks.
12:51
So larger companies command a premium because they're easier to trade. Precisely.
12:55
The public markets simply do not reward small cap transitional companies with
12:59
premium multiples until the transition is completely proven.
13:02
That brings us to the key risks. If you buy the stock for the dividend and wait,
13:08
what could go wrong? What could destroy that thesis?
13:11
The analyst outlines two massive
13:13
structural risks. The first is supplier agreement concentration. Okay.
13:18
Because a huge portion of their business is still rooted in distributing for
13:22
other companies, they are heavily reliant on fixed-term contracts.
13:26
It's essentially rental risk.
13:27
They are renting the right to sell other companies' products.
13:30
And the risk of renting is that the landlord can always kick you out.
13:34
A principal pharmaceutical company can decide at any moment not to renew a contract
13:38
completely, regardless of how well hyphens perform. That is terrifying.
13:42
And it happens. The report cites past losses of partnerships like biosensors
13:46
and a recent termination with Fabrix.
13:49
You can lose a major revenue stream overnight. Okay, what is the second major
13:52
risk? Foreign exchange volatility.
13:55
We covered the Vietnam squeeze, but the report reminds us that Hisense does
13:58
not have a formal policy to hedge against currency swings. They are completely unhedged. Yes.
14:03
So given the ongoing geopolitical environment, the continued strength of the
14:08
euro and the weakness of local Southeast Asian currencies remains a persistent
14:12
threat to their profit margins. Wow.
14:15
Which brings this entire deep dive into a really sharp focus.
14:19
It's the ultimate investor dilemma. You're looking at a cash-generating company
14:23
with a great dividend, but it is currently caught in a massive tug of war. A very intense one.
14:28
It leaves you with a much broader question to ponder.
14:31
Can a regional healthcare distributor successfully transform itself into a high-margin
14:36
brand owner fast enough to outrun the punishing currency and regulatory risks of emerging markets?
14:41
That is the million-dollar question. It really is. That's the transition you
14:45
are betting on if you invest here.
14:46
This content is intended to serve strictly and only as an informational,
14:50
independent, objective summary of recent events and should in no way be interpreted,
14:55
construed or relied upon by any party as inside information or financial advice.